We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Government healthcare programs must require more price transparency and better reporting to stop pharmaceutical companies from overcharging them for medications, according to experts and activists testifying at a House committee hearing.